[
  {
    "citation": "A, C. et al. (2016). [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine]."
  },
  {
    "citation": "Abdolmaleky, H. et al. (2005). Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope."
  },
  {
    "citation": "Adams, W. et al. (2015). Long-term, calorie-restricted intake of a high-fat diet in rats reduces impulse control and ventral striatal D2 receptor signalling - two markers of addiction vulnerability."
  },
  {
    "citation": "Adejare, A. et al. (2023). Brain antioxidant status and gene expressions of nicotinic and dopamine receptors are improved by black seed oil administration in cigarette smoke or nicotine vapour-exposed rats."
  },
  {
    "citation": "Agundez, J. et al. (2013). Anti-Parkinson's disease drugs and pharmacogenetic considerations."
  },
  {
    "citation": "Ahlstrom, S. et al. (2023). Clinical and genetic factors associated with post-operative nausea and vomiting after propofol anaesthesia."
  },
  {
    "citation": "Ahmad, M. et al. (2021). Naringenin alleviates paraquat-induced dopaminergic neuronal loss in SH-SY5Y cells and a rat model of Parkinson's disease."
  },
  {
    "citation": "Akbarian, F. et al. (2019). Novel Insight into Differential Gene Expression and Clinical Significance of Dopamine Receptors, COMT, and IL6 in BPH and Prostate Cancer."
  },
  {
    "citation": "Aklillu, E. et al. (2007). CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine."
  },
  {
    "citation": "Alenius, M. et al. (2008). Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting."
  },
  {
    "citation": "Alladi, C. et al. (2019). Dopamine (DRD2) and Serotonin (HTR2A, 2C) Receptor Gene Polymorphisms do not influence early response to Risperidone in South Indian Patients with Schizophrenia."
  },
  {
    "citation": "Alladi, C. et al. (2017). Risperidone-Induced Adverse Drug Reactions and Role of DRD2 (-141 C Ins/Del) and 5HTR2C (-759 C>T) Genetic Polymorphisms in Patients with Schizophrenia."
  },
  {
    "citation": "Allen, J. et al. (2016). Discovery and clinical introduction of first-in-class imipridone ONC201."
  },
  {
    "citation": "Amir, Q. et al. (2020). Synonymous polymorphism rs201256011 in dopamine receptor type 2 gene is associated with schizophrenia and PANSS score in Pakistani population: A first report."
  },
  {
    "citation": "Anderson, G. et al. (2007). Effects of short- and long-term risperidone treatment on prolactin levels in children with autism."
  },
  {
    "citation": "Andreoli, L. et al. (2021). Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism."
  },
  {
    "citation": "Ankney, B. et al. (2018). Persistent effects of obesity: a neuroplasticity hypothesis."
  },
  {
    "citation": "Annis, A. et al. (2025). Genetic Associations of Persistent Opioid Use After Surgery Point to OPRM1 but Not Other Opioid-Related Loci as the Main Driver of Opioid Use Disorder."
  },
  {
    "citation": "Arai, M. et al. (2024). Enhancement of Haloperidol-Induced Catalepsy by GPR143, an L-Dopa Receptor, in Striatal Cholinergic Interneurons."
  },
  {
    "citation": "Arakawa, R. et al. (2020). PET technology for drug development in psychiatry."
  },
  {
    "citation": "Arbouw, M. et al. (2009). Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease."
  },
  {
    "citation": "Armando, I. et al. (2018). Antihypertensive effect of etamicastat in dopamine D2 receptor-deficient mice."
  },
  {
    "citation": "Arranz, M. et al. (2021). Pharmacogenetics of antipsychotics: Clinical utility and implementation."
  },
  {
    "citation": "Asaoka, N. et al. (2019). An Adenosine A(2A) Receptor Antagonist Improves Multiple Symptoms of Repeated Quinpirole-Induced Psychosis."
  },
  {
    "citation": "Aslostovar, L. et al. (2018). A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia."
  },
  {
    "citation": "Asuni, C. et al. (2007). Association study between clinical response to rizatriptan and some candidate genes."
  },
  {
    "citation": "Athanasoulia, A. et al. (2014). The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas."
  },
  {
    "citation": "Azkona, G. et al. (2014). Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys."
  },
  {
    "citation": "Bakker, P. et al. (2015). [The genetics of antipsychotic-related movement disorders]."
  },
  {
    "citation": "Bakker, P. et al. (2012). Candidate gene-based association study of antipsychotic-induced movement disorders in long-stay psychiatric patients: a prospective study."
  },
  {
    "citation": "Bakker, P. et al. (2008). Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions."
  },
  {
    "citation": "Ballard, M. et al. (2015). Striatal Dopamine D2/D3 Receptor Availability Is Associated with Executive Function in Healthy Controls but Not Methamphetamine Users."
  },
  {
    "citation": "Barratt, D. et al. (2006). Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments."
  },
  {
    "citation": "Basara, N. et al. (2013). Association of dopamine receptor gene polymorphism and psychological personality traits in liability for opioid addiction."
  },
  {
    "citation": "Basu, A. et al. (2024). Pharmacogenomics-assisted schizophrenia management: A hybrid type 2 effectiveness-implementation study protocol to compare the clinical utility, cost-effectiveness, and barriers."
  },
  {
    "citation": "Bawor, M. et al. (2015). Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study."
  },
  {
    "citation": "Beer, F. et al. (2024). Antipsychotic dopamine D(2) affinity and negative symptoms in remitted first episode psychosis patients."
  },
  {
    "citation": "Berardis, D. et al. (2014). Treatment of antipsychotic-induced hyperprolactinemia: an update on the role of the dopaminergic receptors D2 partial agonist aripiprazole."
  },
  {
    "citation": "Bergen, A. et al. (2009). Dopamine genes and nicotine dependence in treatment-seeking and community smokers."
  },
  {
    "citation": "Berlin, I. et al. (2000). Dopaminergic drug response and the genotype (Taq IA polymorphism) of the dopamine D2 receptor."
  },
  {
    "citation": "Bertotto, L. et al. (2024). Effects of the Phosphodiesterase 10A Inhibitor MR1916 on Alcohol Self-Administration and Striatal Gene Expression in Post-Chronic Intermittent Ethanol-Exposed Rats."
  },
  {
    "citation": "Beyer, J. et al. (2016). Adjunctive brexpiprazole for the treatment of major depressive disorder."
  },
  {
    "citation": "Bharti, N. et al. (2021). Genetic diversity of 'Very Important Pharmacogenes' in two South-Asian populations."
  },
  {
    "citation": "Bialecka, M. et al. (2008). [Pharmacogenetics in Parkinson's disease treatment]."
  },
  {
    "citation": "Bishop, J. et al. (2015). Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia."
  },
  {
    "citation": "Biswas, M. et al. (2023). Pharmacogenomics and non-genetic factors affecting drug response in autism spectrum disorder in Thai and other populations: current evidence and future implications."
  },
  {
    "citation": "Biswas, M. et al. (2022). Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder."
  },
  {
    "citation": "Blasi, G. et al. (2015). Variation in Dopamine D2 and Serotonin 5-HT2A Receptor Genes is Associated with Working Memory Processing and Response to Treatment with Antipsychotics."
  },
  {
    "citation": "Blasi, G. et al. (2011). DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia."
  },
  {
    "citation": "Bloemen, O. et al. (2013). Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis."
  },
  {
    "citation": "Blum, K. et al. (2022). Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of \"Dopamine Homeostasis\"."
  },
  {
    "citation": "Blum, K. et al. (2017). Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape."
  },
  {
    "citation": "Blum, K. et al. (2009). Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing \"deprivation-amplification relapse therapy\" (DART)."
  },
  {
    "citation": "Blum, K. et al. (2008). LG839: anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome."
  },
  {
    "citation": "Blum, K. et al. (2007). Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis."
  },
  {
    "citation": "Blum, K. et al. (1996). Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report."
  },
  {
    "citation": "Blum, K. et al. (1995). Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour."
  },
  {
    "citation": "Blum, K. et al. (1994). Prolonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele."
  },
  {
    "citation": "Bousman, C. et al. (2015). Effects of COMT, DRD2, BDNF, and APOE Genotypic Variation on Treatment Efficacy and Cognitive Side Effects of Electroconvulsive Therapy."
  },
  {
    "citation": "Bramness, J. et al. (2016). Psychosis induced by amphetamines."
  },
  {
    "citation": "Breitling, L. et al. (2010). Prospective association of dopamine-related polymorphisms with smoking cessation in general care."
  },
  {
    "citation": "Brennan, M. et al. (2014). Pharmacogenetics of second-generation antipsychotics."
  },
  {
    "citation": "Brousse, G. et al. (2010). Could the inter-individual variability in cocaine-induced psychotic effects influence the development of cocaine addiction? Towards a new pharmacogenetic approach to addictions."
  },
  {
    "citation": "Buck, K. et al. (2000). Mapping quantitative trait loci that regulate sensitivity and tolerance to quinpirole, a dopamine mimetic selective for D(2)/D(3) receptors."
  },
  {
    "citation": "Bueno, C. et al. (2017). Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment."
  },
  {
    "citation": "Burstein, O. et al. (2017). Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression."
  },
  {
    "citation": "Cabaleiro, T. et al. (2013). Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects."
  },
  {
    "citation": "Cacabelos, R. et al. (2021). Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics."
  },
  {
    "citation": "Calarge, C. et al. (2009). Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents."
  },
  {
    "citation": "Cargnin, S. et al. (2014). Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache."
  },
  {
    "citation": "Carlin, J. et al. (2016). Removal of high-fat diet after chronic exposure drives binge behavior and dopaminergic dysregulation in female mice."
  },
  {
    "citation": "Carvalho, C. et al. (2022). Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms."
  },
  {
    "citation": "Carvalho, L. et al. (2019). High-fat diet withdrawal modifies alcohol preference and transcription of dopaminergic and GABAergic receptors."
  },
  {
    "citation": "Charan, A. et al. (2016). Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia."
  },
  {
    "citation": "Chen, S. et al. (2009). Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors."
  },
  {
    "citation": "Cheng, Y. et al. (2023). Multi-trait genome-wide association analyses leveraging alcohol use disorder findings identify novel loci for smoking behaviors in the Million Veteran Program."
  },
  {
    "citation": "Cheng, Z. et al. (2023). Rasd2 Mediates Acute Fasting-Induced Antidepressant-Like Effects via Dopamine D2 Receptor Activation in Ovariectomized Mice."
  },
  {
    "citation": "Cherrier, K. et al. (2020). Cocaine-mediated circadian reprogramming in the striatum through dopamine D2R and PPARgamma activation."
  },
  {
    "citation": "Chi, A. et al. (2019). Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201."
  },
  {
    "citation": "Chiesa, A. et al. (2014). Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression."
  },
  {
    "citation": "Choi, C. et al. (2015). High sucrose consumption during pregnancy induced ADHD-like behavioral phenotypes in mice offspring."
  },
  {
    "citation": "Choi, H. et al. (2015). Lack of association between DRD2 Taq1A gene polymorphism and smoking cessation therapy: a meta-analysis."
  },
  {
    "citation": "Chong, S. et al. (2003). Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia."
  },
  {
    "citation": "Chu, C. et al. (2019). Association Between Polymorphisms in Dopamine-Related Genes and Orthopedic Pain Expression in a Chinese Elderly Population."
  },
  {
    "citation": "Chun, S. et al. (2014). Specific disruption of thalamic inputs to the auditory cortex in schizophrenia models."
  },
  {
    "citation": "Ciano, P. et al. (2016). Varenicline-Induced Elevation of Dopamine in Smokers: A Preliminary [(11)C]-(+)-PHNO PET Study."
  },
  {
    "citation": "Cinciripini, P. et al. (2004). The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood."
  },
  {
    "citation": "Clarke, W. et al. (2013). Signalling profile differences: paliperidone versus risperidone."
  },
  {
    "citation": "Clauss, N. et al. (2022). The Modification of Offspring Stress-Related Behavior and the Expression of Drd1, Drd2, and Nr3c1 by a Western-Pattern Diet in Mus Musculus."
  },
  {
    "citation": "Coelho, M. et al. (2019). Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles."
  },
  {
    "citation": "Colizzi, M. et al. (2015). Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis."
  },
  {
    "citation": "Colzato, L. et al. (2016). Effects of l-Tyrosine on working memory and inhibitory control are determined by DRD2 genotypes: A randomized controlled trial."
  },
  {
    "citation": "Comings, D. et al. (1996). A study of the dopamine D2 receptor gene in pathological gambling."
  },
  {
    "citation": "Comings, D. et al. (1996). The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking."
  },
  {
    "citation": "Connor, J. et al. (2007). Heavy nicotine and alcohol use in alcohol dependence is associated with D2 dopamine receptor (DRD2) polymorphism."
  },
  {
    "citation": "Cormier, F. et al. (2013). Genetics of impulse control disorders in Parkinson's disease."
  },
  {
    "citation": "Correia, C. et al. (2010). Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions."
  },
  {
    "citation": "Cravchik, A. et al. (1999). Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants."
  },
  {
    "citation": "Crettol, S. et al. (2008). Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment."
  },
  {
    "citation": "Crowley, J. et al. (2012). Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice."
  },
  {
    "citation": "Cruz, A. et al. (2021). Dopamine Receptors in Cancer: Are They Valid Therapeutic Targets?"
  },
  {
    "citation": "Cui, Y. et al. (2018). Dopamine receptor D2 gene polymorphism, urine fluoride, and intelligence impairment of children in China: A school-based cross-sectional study."
  },
  {
    "citation": "Cunha, F. et al. (2015). Both food restriction and high-fat diet during gestation induce low birth weight and altered physical activity in adult rat offspring: the \"Similarities in the Inequalities\" model."
  },
  {
    "citation": "Custodio, R. et al. (2020). 25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential."
  },
  {
    "citation": "Dao, C. et al. (2021). The impact of removing former drinkers from genome-wide association studies of AUDIT-C."
  },
  {
    "citation": "David, S. et al. (2007). Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials."
  },
  {
    "citation": "David, S. et al. (2007). Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation."
  },
  {
    "citation": "David, S. et al. (2003). Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?"
  },
  {
    "citation": "Dehelean, L. et al. (2021). Impairment of the cardiac ejection fraction by blocking dopamine D2 receptors induced by long-acting injectable antipsychotic treatment."
  },
  {
    "citation": "Demin, A. et al. (2014). [Modern approaches to the primary prevention of the development of psychoactive substance dependence on the base of accounting of environmental and genetic risk factors]."
  },
  {
    "citation": "Deng, X. et al. (2015). Association between DRD2/ANKK1 TaqIA polymorphism and common illicit drug dependence: evidence from a meta-analysis."
  },
  {
    "citation": "Deshetty, U. et al. (2021). Menthol, a bioactive constituent of Mentha, attenuates motion sickness in mice model: Involvement of dopaminergic system."
  },
  {
    "citation": "Devincci, A. et al. (2025). Longitudinal sex-specific impacts of high-fat diet on dopaminergic dysregulation and behavior from periadolescence to late adulthood."
  },
  {
    "citation": "DiNieri, J. et al. (2011). Maternal cannabis use alters ventral striatal dopamine D2 gene regulation in the offspring."
  },
  {
    "citation": "Docherty, A. et al. (2023). GWAS Meta-Analysis of Suicide Attempt: Identification of 12 Genome-Wide Significant Loci and Implication of Genetic Risks for Specific Health Factors."
  },
  {
    "citation": "Dolzan, V. et al. (2007). Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment."
  },
  {
    "citation": "Domschke, K. et al. (2013). Clinical and molecular genetics of psychotic depression."
  },
  {
    "citation": "Dorey, E. et al. (2018). The impact of periconceptional alcohol exposure on fat preference and gene expression in the mesolimbic reward pathway in adult rat offspring."
  },
  {
    "citation": "Drtilkova, I. et al. (2008). Clinical and molecular-genetic markers of ADHD in children."
  },
  {
    "citation": "Duan, L. et al. (2018). [Association between DRD2 gene polymorphisms and the dosage used on methadone maintenance treatment program]."
  },
  {
    "citation": "Duric, G. et al. (2009). [Dopa-responsive dystonia]."
  },
  {
    "citation": "During, S. et al. (2019). Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D(2/3) receptor blockade - An exploratory study."
  },
  {
    "citation": "Dusitanond, P. et al. (2009). Neuroleptics and migraine."
  },
  {
    "citation": "Ebdrup, B. et al. (2016). Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade."
  },
  {
    "citation": "Emig, H. et al. (2016). Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology."
  },
  {
    "citation": "Epstein, L. et al. (2004). Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers."
  },
  {
    "citation": "Escamilla, R. et al. (2018). Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia."
  },
  {
    "citation": "Esdonk, M. et al. (2019). The Pharmacodynamic Effects of a Dopamine-Somatostatin Chimera Agonist on the Cardiovascular System."
  },
  {
    "citation": "Eum, S. et al. (2017). Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report."
  },
  {
    "citation": "Fan, Y. et al. (2022). Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer."
  },
  {
    "citation": "Fan, X. et al. (2018). Dopamine Receptor Agonist Treatment of Idiopathic Dystonia: A Reappraisal in Humans and Mice."
  },
  {
    "citation": "Fedorenko, O. et al. (2020). Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia."
  },
  {
    "citation": "Feistauer, V. et al. (2020). Restriction and hyperlipidic diets during pregnancy, lactation and adult life modified the expression of dopaminergic system related genes both in female mice and their adult offspring."
  },
  {
    "citation": "Ferrero, H. et al. (2014). Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in vitro: implications for treatment of ovarian hyperstimulation syndrome with dopamine receptor 2 agonists."
  },
  {
    "citation": "Fidry, M. et al. (2024). Pharmacogenetic Testing in Treatment-resistant Panic Disorder: a Preliminary Analysis."
  },
  {
    "citation": "Filopanti, M. et al. (2010). Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas."
  },
  {
    "citation": "Filopanti, M. et al. (2008). Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas."
  },
  {
    "citation": "Finckh, U. et al. (1997). Influence of the dopamine D2 receptor (DRD2) genotype on neuroadaptive effects of alcohol and the clinical outcome of alcoholism."
  },
  {
    "citation": "Florez, G. et al. (2008). Association between the Stin2 VNTR polymorphism of the serotonin transporter gene and treatment outcome in alcohol-dependent patients."
  },
  {
    "citation": "Flynn, M. et al. (2017). Mechanism of Off-Target Interactions and Toxicity of Tamoxifen and Its Metabolites."
  },
  {
    "citation": "Foll, B. et al. (2016). Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans."
  },
  {
    "citation": "Forrester, S. et al. (2020). Depression Onset in Long-term Adolescent Cannabinoid Use: A Neurobiological Review."
  },
  {
    "citation": "Franklin, J. et al. (2021). Cannabinoid 2 receptors regulate dopamine 2 receptor expression by a beta-arrestin 2 and GRK5-dependent mechanism in neuronal cells."
  },
  {
    "citation": "Frederick, N. et al. (2021). Pharmacological perturbation reveals deficits in D2 receptor responses in Thap1 null mice."
  },
  {
    "citation": "Free, R. et al. (2021). Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D(2) Dopamine Receptor."
  },
  {
    "citation": "Freeman, T. et al. (2013). Dopaminergic involvement in effort-based but not impulsive reward processing in smokers."
  },
  {
    "citation": "Frey, U. et al. (2016). Postoperative nausea and vomiting: The role of the dopamine D2 receptor TaqIA polymorphism."
  },
  {
    "citation": "Furukori, N. et al. (2011). Comparing the influence of dopamine D(2) polymorphisms and plasma drug concentrations on the clinical response to risperidone."
  },
  {
    "citation": "Furukori, N. et al. (2008). Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients."
  },
  {
    "citation": "Gao, Z. et al. (2023). Potential effect of antidepressants on remission from cocaine use disorder - A nationwide matched retrospective cohort study."
  },
  {
    "citation": "Gao, Z. et al. (2023). Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration and mechanism of action analyses."
  },
  {
    "citation": "Gao, L. et al. (2018). A computational network analysis based on targets of antipsychotic agents."
  },
  {
    "citation": "Gasso, P. et al. (2020). Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period."
  },
  {
    "citation": "Gasso, P. et al. (2018). Impact of NTRK2, DRD2 and ACE polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis."
  },
  {
    "citation": "Gasso, P. et al. (2009). A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms."
  },
  {
    "citation": "Georgiou, P. et al. (2016). Methamphetamine abstinence induces changes in mu-opioid receptor, oxytocin and CRF systems: Association with an anxiogenic phenotype."
  },
  {
    "citation": "Ghanbarzehi, A. et al. (2023). Disclosing common biological signatures and predicting new therapeutic targets in schizophrenia and obsessive-compulsive disorder by integrated bioinformatics analysis."
  },
  {
    "citation": "Giegling, I. et al. (2013). Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol."
  },
  {
    "citation": "Gilbert, D. et al. (2009). Neurotransmission-related genetic polymorphisms, negative affectivity traits, and gender predict tobacco abstinence symptoms across 44 days with and without nicotine patch."
  },
  {
    "citation": "Girgis, R. et al. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO."
  },
  {
    "citation": "Gold, M. et al. (2014). Low dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children?"
  },
  {
    "citation": "Gomeni, R. et al. (2013). A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone."
  },
  {
    "citation": "Gressier, F. et al. (2016). Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis."
  },
  {
    "citation": "Guin, D. et al. (2017). A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson's disease."
  },
  {
    "citation": "Gunes, A. et al. (2007). Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients."
  },
  {
    "citation": "Gutierrez, A. et al. (2019). Effects of intrastriatal dopamine D1 or D2 antagonists on methamphetamine-induced egocentric and allocentric learning and memory deficits in Sprague-Dawley rats."
  },
  {
    "citation": "Guzey, C. et al. (2011). Allele and genotype frequencies of serotonin and dopamine transporter and receptor polymorphisms in a Norwegian population."
  },
  {
    "citation": "Guzey, C. et al. (2007). Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms."
  },
  {
    "citation": "Hadithy, A. et al. (2009). Lack of association between antipsychotic-induced Parkinsonism or its subsymptoms and rs4606 SNP of RGS2 gene in African-Caribbeans and the possible role of the medication: the Curacao extrapyramidal syndromes study X."
  },
  {
    "citation": "Hadithy, A. et al. (2008). Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors."
  },
  {
    "citation": "Hajj, A. et al. (2022). Clinical and genetic factors associated with self-reported cognitive deficits in women with breast cancer: the \"CAGE-Cog\" study."
  },
  {
    "citation": "Hajj, A. et al. (2022). Fatigue in breast cancer patients on chemotherapy: a cross-sectional study exploring clinical, biological, and genetic factors."
  },
  {
    "citation": "Hajj, A. et al. (2021). Clinical and genetic factors associated with anxiety and depression in breast cancer patients: a cross-sectional study."
  },
  {
    "citation": "Hajj, A. et al. (2021). Negative symptoms in schizophrenia: correlation with clinical and genetic factors."
  },
  {
    "citation": "Hajj, A. et al. (2021). Clinical and Genetic Factors Associated With the Breast Cancer-Related Sleep Disorders: The \"CAGE-Sleep\" Study-A Cross-Sectional Study."
  },
  {
    "citation": "Hajj, A. et al. (2019). Clinical and Genetic Factors Associated with Resistance to Treatment in Patients with Schizophrenia: A Case-Control Study."
  },
  {
    "citation": "Hakim, J. et al. (2019). Prolonged ad libitum access to low-concentration sucrose changes the neurochemistry of the nucleus accumbens in male Sprague-Dawley rats."
  },
  {
    "citation": "Hamidovic, A. et al. (2009). Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants."
  },
  {
    "citation": "Hart, A. et al. (2013). Candidate gene studies of a promising intermediate phenotype: failure to replicate."
  },
  {
    "citation": "He, Y. et al. (2021). Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors."
  },
  {
    "citation": "Hedenmalm, K. et al. (2006). Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms."
  },
  {
    "citation": "Heidari, A. et al. (2024). Parental Exposure to Morphine Before Conception Decreases Morphine and Cocaine-Induced Locomotor Sensitization in Male Offspring."
  },
  {
    "citation": "Herman, A. et al. (2014). Pharmacogenetics of nicotine addiction: role of dopamine."
  },
  {
    "citation": "Hirth, N. et al. (2016). Convergent evidence from alcohol-dependent humans and rats for a hyperdopaminergic state in protracted abstinence."
  },
  {
    "citation": "Hong, C. et al. (2010). Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment."
  },
  {
    "citation": "Houston, J. et al. (2012). Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia."
  },
  {
    "citation": "Houston, J. et al. (2011). Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women."
  },
  {
    "citation": "Houston, J. et al. (2010). Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients."
  },
  {
    "citation": "Hu, J. et al. (2006). No evidence for a major role of polymorphisms during bupropion treatment."
  },
  {
    "citation": "Huang, T. et al. (2016). A new method for identifying causal genes of schizophrenia and anti-tuberculosis drug-induced hepatotoxicity."
  },
  {
    "citation": "Huang, E. et al. (2016). Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response."
  },
  {
    "citation": "Huang, C. et al. (2015). Cocaine Withdrawal Impairs mGluR5-Dependent Long-Term Depression in Nucleus Accumbens Shell Neurons of Both Direct and Indirect Pathways."
  },
  {
    "citation": "Hung, C. et al. (2011). Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients."
  },
  {
    "citation": "Hwang, R. et al. (2011). Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response."
  },
  {
    "citation": "ianenko, V. et al. (2014). [Use of itopride in the symptoms of functional dyspepsia in Russia: results of a phase IV prospective open-label multicenter clinical trial]."
  },
  {
    "citation": "Ikeda, M. et al. (2008). Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia."
  },
  {
    "citation": "Ilhan, M. et al. (2015). Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?"
  },
  {
    "citation": "Isaza, C. et al. (2013). Genetic variants associated with addictive behavior in Colombian addicted and non-addicted to heroin or cocaine."
  },
  {
    "citation": "Ishii, M. et al. (2012). Negative predictors of clinical response to triptans in patients with migraine."
  },
  {
    "citation": "Islam, F. et al. (2021). Pharmacogenetics-Guided Advances in Antipsychotic Treatment."
  },
  {
    "citation": "Ivanov, H. et al. (2021). Exploring pharmacogenetic variation in a Bulgarian psychiatric cohort."
  },
  {
    "citation": "Ivashchenko, D. et al. (2020). Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation."
  },
  {
    "citation": "Iwata, Y. et al. (2016). Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia."
  },
  {
    "citation": "Jain, M. et al. (2012). A cooperative interaction between LPHN3 and 11q doubles the risk for ADHD."
  },
  {
    "citation": "Jeon, H. et al. (2023). Dopamine receptor D2 regulates glioblastoma survival and death through MET and death receptor 4/5."
  },
  {
    "citation": "Jerome, R. et al. (2020). Exploring Biologic Predictors Response Disparities to Atypical Antipsychotics among Blacks: A Quasi-Systematic Review."
  },
  {
    "citation": "Johnson, A. et al. (2008). Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues."
  },
  {
    "citation": "Johnstone, E. et al. (2004). Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch."
  },
  {
    "citation": "Junior, A. et al. (2016). Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents."
  },
  {
    "citation": "Junior, A. et al. (2015). Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects."
  },
  {
    "citation": "ka, N. et al. (2014). [USAGE OF PRONORAN(R) FOR TREATMENT OF ELDERLY PATIENTS WITH MILD COGNITIVE IMPAIRMENT]."
  },
  {
    "citation": "Kaiser, R. et al. (2003). L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism."
  },
  {
    "citation": "Kaiser, R. et al. (2002). Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia."
  },
  {
    "citation": "Kalla, P. et al. (2023). Contrasting ABCB1 pharmacogenetics and psychotropic responses in child and adolescent psychiatry: a case comparison."
  },
  {
    "citation": "Kanahara, N. et al. (2020). The effectiveness of very slow switching to aripiprazole in schizophrenia patients with dopamine supersensitivity psychosis: a case series from an open study."
  },
  {
    "citation": "Kang, S. et al. (2015). DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment."
  },
  {
    "citation": "Kang, S. et al. (2008). Association study between antipsychotics- induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia."
  },
  {
    "citation": "Kaplan, N. et al. (2014). Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease."
  },
  {
    "citation": "Kaur, G. et al. (2017). Identification of genetic correlates of response to Risperidone: Findings of a multicentric schizophrenia study from India."
  },
  {
    "citation": "Keks, N. et al. (2020). Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia."
  },
  {
    "citation": "Kibitov, A. et al. (2023). The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders."
  },
  {
    "citation": "Kim, S. et al. (2012). Neuropathology markers and pathways associated with molecular targets for antipsychotic drugs in postmortem brain tissues: exploration of drug targets through the Stanley Neuropathology Integrative Database."
  },
  {
    "citation": "Kimura, M. et al. (2021). Effects of repeated electroconvulsive shocks on dopamine supersensitivity psychosis model rats."
  },
  {
    "citation": "Kinoshita, I. et al. (2025). Co-Expression of Tardive Dyskinesia and Drug-Induced Parkinsonism in Rats Chronically Treated With Haloperidol."
  },
  {
    "citation": "Kishida, I. et al. (2003). Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene."
  },
  {
    "citation": "Kleinjan, M. et al. (2015). Parental smoke exposure and the development of nicotine craving in adolescent novice smokers: the roles of DRD2, DRD4, and OPRM1 genotypes."
  },
  {
    "citation": "Klepstad, P. et al. (2011). Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients."
  },
  {
    "citation": "Knol, W. et al. (2013). Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach."
  },
  {
    "citation": "Kohlrausch, F. et al. (2008). Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics."
  },
  {
    "citation": "Kohno, M. et al. (2016). Midbrain functional connectivity and ventral striatal dopamine D2-type receptors: link to impulsivity in methamphetamine users."
  },
  {
    "citation": "Koller, D. et al. (2021). Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial."
  },
  {
    "citation": "Koller, D. et al. (2020). The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial."
  },
  {
    "citation": "Koller, D. et al. (2020). Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers."
  },
  {
    "citation": "Koller, D. et al. (2018). Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects."
  },
  {
    "citation": "Kondo, T. et al. (2003). Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients."
  },
  {
    "citation": "Koning, J. et al. (2012). Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients."
  },
  {
    "citation": "Kordas, K. et al. (2011). A dopamine receptor (DRD2) but not dopamine transporter (DAT1) gene polymorphism is associated with neurocognitive development of Mexican preschool children with lead exposure."
  },
  {
    "citation": "Korlatowicz, A. et al. (2021). Identification of Molecular Markers of Clozapine Action in Ketamine-Induced Cognitive Impairment: A GPCR Signaling PathwayFinder Study."
  },
  {
    "citation": "Kovaleva, K. et al. (2024). GENETIC VARIANTS IN ANTIPSYCHOTIC METABOLISM: POLYMORPHISM PROFILES IN KAZAKH COHORT WITH PARANOID SCHIZOPHRENIA."
  },
  {
    "citation": "Kraemmer, J. et al. (2016). Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease."
  },
  {
    "citation": "Kravtsov, V. et al. (2020). [Pharmacogenetic aspects of the dopaminergic system in clozapine pharmacodynamics]."
  },
  {
    "citation": "Krupkova, M. et al. (2018). Single-Gene Congenic Strain Reveals the Effect of Zbtb16 on Dexamethasone-Induced Insulin Resistance."
  },
  {
    "citation": "Kubi, P. et al. (2019). Probing Binding Landscapes and Molecular Recognition Mechanisms of Atypical Antipsychotic Drugs towards the Selective Targeting of D(2) Dopamine Receptor."
  },
  {
    "citation": "Kurylev, A. et al. (2018). The combined effect of CYP2D6 and DRD2 Taq1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study)."
  },
  {
    "citation": "Kusters, C. et al. (2018). Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease."
  },
  {
    "citation": "Kwak, Y. et al. (2013). Task-dependent interactions between dopamine D2 receptor polymorphisms and L-DOPA in patients with Parkinson's disease."
  },
  {
    "citation": "Kwon, J. et al. (2008). Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole."
  },
  {
    "citation": "Lafuente, A. et al. (2008). Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders."
  },
  {
    "citation": "Lai, I. et al. (2011). Analysis of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia."
  },
  {
    "citation": "Lako, I. et al. (2013). Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis."
  },
  {
    "citation": "Lakshmi, Y. et al. (2023). Unravelling the Molecular Mechanisms of a Quercetin Nanocrystal for Treating Potential Parkinson's Disease in a Rotenone Model: Supporting Evidence of Network Pharmacology and In Silico Data Analysis."
  },
  {
    "citation": "Lambert, J. et al. (2024). Association of genetic variants in CYP3A5, DRD2 and NK1R with opioid overdose."
  },
  {
    "citation": "Landi, S. et al. (2003). Evaluation of a microarray for genotyping polymorphisms related to xenobiotic metabolism and DNA repair."
  },
  {
    "citation": "Lane, H. et al. (2005). Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics."
  },
  {
    "citation": "Lane, H. et al. (2004). Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function."
  },
  {
    "citation": "Lattuada, E. et al. (2004). Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment."
  },
  {
    "citation": "Laugsand, E. et al. (2011). Clinical and genetic factors associated with nausea and vomiting in cancer patients receiving opioids."
  },
  {
    "citation": "Lawford, B. et al. (2013). DRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia."
  },
  {
    "citation": "Lawford, B. et al. (2012). Alcohol Use Disorders Identification Test (AUDIT) scores are elevated in antipsychotic-induced hyperprolactinaemia."
  },
  {
    "citation": "Lawford, B. et al. (2003). D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder."
  },
  {
    "citation": "Lawford, B. et al. (2000). The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment."
  },
  {
    "citation": "Lawford, B. et al. (1995). Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele."
  },
  {
    "citation": "Leddy, J. et al. (2009). Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths."
  },
  {
    "citation": "Lee, S. et al. (2012). Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response."
  },
  {
    "citation": "Lee, S. et al. (2012). The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder."
  },
  {
    "citation": "Lee, H. et al. (2011). Genetics of tardive dyskinesia."
  },
  {
    "citation": "Lee, J. et al. (2011). Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease."
  },
  {
    "citation": "Lencer, R. et al. (2014). Association of variants in DRD2 and GRM3 with motor and cognitive function in first-episode psychosis."
  },
  {
    "citation": "Lencz, T. et al. (2015). Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic."
  },
  {
    "citation": "Lencz, T. et al. (2010). DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia."
  },
  {
    "citation": "Lencz, T. et al. (2009). Pharmacogenetics of antipsychotic-induced side effects."
  },
  {
    "citation": "Lencz, T. et al. (2006). DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients."
  },
  {
    "citation": "Leon, J. et al. (2008). A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I."
  },
  {
    "citation": "Leon, J. et al. (2005). Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness."
  },
  {
    "citation": "Lerman, C. et al. (2006). Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials."
  },
  {
    "citation": "Lerman, C. et al. (2004). Changes in food reward following smoking cessation: a pharmacogenetic investigation."
  },
  {
    "citation": "Lerman, C. et al. (2003). Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial."
  },
  {
    "citation": "Lett, T. et al. (2012). Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications."
  },
  {
    "citation": "Levchenko, A. et al. (2019). No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia."
  },
  {
    "citation": "Levran, O. et al. (2014). Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variants."
  },
  {
    "citation": "Levy, F. et al. (2014). Stimulant side effects: prefrontal/basal ganglia circuit control at dopamine D1/D2 receptors."
  },
  {
    "citation": "Lewandrowski, K. et al. (2024). A Pharmacogenomics-Based In Silico Investigation of Opioid Prescribing in Post-operative Spine Pain Management and Personalized Therapy."
  },
  {
    "citation": "Li, S. et al. (2024). The Activation of p300 Enhances the Sensitivity of Pituitary Adenomas to Dopamine Agonist Treatment by Regulating the Transcription of DRD2."
  },
  {
    "citation": "Li, Y. et al. (2024). Chronic pharmacologic manipulation of dopamine transmission ameliorates metabolic disturbance in Trappc9-linked brain developmental syndrome."
  },
  {
    "citation": "Li, C. et al. (2024). Molecular mechanisms of quetiapine bidirectional regulation of bipolar depression and mania based on network pharmacology and molecular docking: Evidence from computational biology."
  },
  {
    "citation": "Li, H. et al. (2024). Vitamin D3 improves iminodipropionitrile-induced tic-like behavior in rats through regulation of GDNF/c-Ret signaling activity."
  },
  {
    "citation": "Li, X. et al. (2022). Effects of Long-Term Administration of Q808 on Hippocampal Transcriptome in Healthy Rats."
  },
  {
    "citation": "Li, S. et al. (2021). Study on Hepatotoxicity of Rhubarb Based on Metabolomics and Network Pharmacology."
  },
  {
    "citation": "Li, H. et al. (2021). Pepper component 7-ethoxy-4-methylcoumarin, a novel dopamine D2 receptor agonist, ameliorates experimental Parkinson's disease in mice and Caenorhabditis elegans."
  },
  {
    "citation": "Li, J. et al. (2019). Candidate gene analyses for acute pain and morphine analgesia after pediatric day surgery: African American versus European Caucasian ancestry and dose prediction limits."
  },
  {
    "citation": "Liang, Y. et al. (2023). Study on Anti-Constipation Effects of Hemerocallis citrina Baroni through a Novel Strategy of Network Pharmacology Screening."
  },
  {
    "citation": "Liou, Y. et al. (2008). The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia."
  },
  {
    "citation": "Liu, Y. et al. (2024). Reviving: restoring depression-like behaviour through glial cell-derived neurotrophic factor treatment in the medial prefrontal cortex."
  },
  {
    "citation": "Liu, J. et al. (2023). Pharmacogenomics-a New Frontier for Individualized Treatment of Parkinson's Disease."
  },
  {
    "citation": "Liu, X. et al. (2023). Dopamine D2 receptor agonist Bromocriptine ameliorates Abeta(1-42)-induced memory deficits and neuroinflammation in mice."
  },
  {
    "citation": "Liu, Y. et al. (2022). beta-Arrestin2-biased Drd2 agonist UNC9995 alleviates astrocyte inflammatory injury via interaction between beta-arrestin2 and STAT3 in mouse model of depression."
  },
  {
    "citation": "Liu, Y. et al. (2020). The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment."
  },
  {
    "citation": "Liu, Y. et al. (2009). Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients."
  },
  {
    "citation": "Llerena, A. et al. (2013). Pharmacogenetics of clinical response to risperidone."
  },
  {
    "citation": "Lopez, O. et al. (2019). Interactions between DRD2/ANKK1 TaqIA Polymorphism and Dietary Factors Influence Plasma Triglyceride Concentrations in Diabetic Patients from Western Mexico: A Cross-sectional Study."
  },
  {
    "citation": "Lotsch, J. et al. (2009). Genetic modulation of the pharmacological treatment of pain."
  },
  {
    "citation": "Loureiro, C. et al. (2023). Lifetime cannabis use and childhood trauma associated with CNR1 genetic variants increase the risk of psychosis: findings from the STREAM study."
  },
  {
    "citation": "Low, J. et al. (2024). Genetic susceptibility to caffeine intake and metabolism: a systematic review."
  },
  {
    "citation": "Lu, K. et al. (2021). Dopamine Prevents Ultraviolet B-induced Development and Progression of Premalignant Cutaneous Lesions through its D(2) Receptors."
  },
  {
    "citation": "Lu, J. et al. (2018). Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia."
  },
  {
    "citation": "Lucht, M. et al. (2001). Influence of the dopamine D2 receptor (DRD2) exon 8 genotype on efficacy of tiapride and clinical outcome of alcohol withdrawal."
  },
  {
    "citation": "Luijten, M. et al. (2013). The role of dopamine in inhibitory control in smokers and non-smokers: a pharmacological fMRI study."
  },
  {
    "citation": "Luo, T. et al. (2024). Network pharmacology screening, in vitro and in vivo evaluation of antianxiety and antidepressant drug-food analogue."
  },
  {
    "citation": "Luo, D. et al. (2020). Lithium for schizophrenia: supporting evidence from a 12-year, nationwide health insurance database and from Akt1-deficient mouse and cellular models."
  },
  {
    "citation": "Luque, G. et al. (2011). Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas."
  },
  {
    "citation": "Lv, H. et al. (2012). Effects of ningdong granule on DA, DRD2, and HVA in a rat model of Tourette's syndrome."
  },
  {
    "citation": "Ma, S. et al. (2024). Role of ruscogenin extracted from Radix Ophiopogon Japonicus in antagonizing 5-hydroxytryptamine and dopamine receptors through computational screening."
  },
  {
    "citation": "Ma, L. et al. (2019). Association of dopamine D2 receptor gene polymorphisms with prolactin levels related to risperidone treatment: A systematic review and meta-analysis."
  },
  {
    "citation": "Ma, L. et al. (2019). Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis."
  },
  {
    "citation": "Maestre, E. et al. (2010). Identification and quantification of dopamine receptor 2 in human eutopic and ectopic endometrium: a novel molecular target for endometriosis therapy."
  },
  {
    "citation": "Makoff, A. et al. (2000). Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease."
  },
  {
    "citation": "Malhotra, A. et al. (2004). Candidate gene studies of antipsychotic drug efficacy and drug-induced weight gain."
  },
  {
    "citation": "Mallakh, R. et al. (2013). The dopamine D4/D2 receptor antagonist affinity ratio as a predictor of anti-aggression medication efficacy."
  },
  {
    "citation": "Mallet, J. et al. (2019). Major Depressive Disorder (MDD) and Schizophrenia- Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review."
  },
  {
    "citation": "Manchia, M. et al. (2009). No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample."
  },
  {
    "citation": "Mao, Y. et al. (2022). The Food and Drug Administration-approved antipsychotic drug trifluoperazine, a calmodulin antagonist, inhibits viral replication through PERK-eIF2alpha axis."
  },
  {
    "citation": "Markovic, M. et al. (2017). Brexpiprazole."
  },
  {
    "citation": "Mas, S. et al. (2016). Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes."
  },
  {
    "citation": "Mascia, A. et al. (1998). Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data."
  },
  {
    "citation": "Masellis, M. et al. (2016). Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study."
  },
  {
    "citation": "Mathis, T. et al. (2024). DRD2 activation inhibits choroidal neovascularization in patients with Parkinson's disease and age-related macular degeneration."
  },
  {
    "citation": "McCarthy, D. et al. (2018). Nicotine exposure of male mice produces behavioral impairment in multiple generations of descendants."
  },
  {
    "citation": "McClay, J. et al. (2011). Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia."
  },
  {
    "citation": "McCracken, J. et al. (2014). Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders."
  },
  {
    "citation": "McDonell, K. et al. (2018). Taq1A polymorphism and medication effects on inhibitory action control in Parkinson disease."
  },
  {
    "citation": "Meimei, C. et al. (2022). Discovery of Taxus chinensis fruit wine as potentially functional food against Alzheimer's disease by UHPLC-QE-MS/MS, network pharmacology and molecular docking."
  },
  {
    "citation": "Mihara, K. et al. (2001). Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol."
  },
  {
    "citation": "Mihara, K. et al. (2001). No relationship between--141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study."
  },
  {
    "citation": "Mihara, K. et al. (2000). No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study."
  },
  {
    "citation": "Mihara, K. et al. (2000). Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene."
  },
  {
    "citation": "Miller, N. et al. (2018). Dopaminergic polymorphisms associated with medication responsiveness of gait in Parkinson's disease."
  },
  {
    "citation": "Miller, D. et al. (2010). Acute intravenous synaptamine complex variant KB220 \"normalizes\" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports."
  },
  {
    "citation": "Miura, I. et al. (2012). Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia."
  },
  {
    "citation": "Moeller, S. et al. (2018). Low Striatal Dopamine D2-type Receptor Availability is Linked to Simulated Drug Choice in Methamphetamine Users."
  },
  {
    "citation": "Molitch, M. et al. (2020). Dopamine agonists and antipsychotics."
  },
  {
    "citation": "Moon, J. et al. (2024). Possible genetic biomarker associated with antipsychotic-induced amenorrhea in female patients with schizophrenia."
  },
  {
    "citation": "Moore, T. et al. (2014). Pharmacogenomics in psychiatry: implications for practice."
  },
  {
    "citation": "Moriguchi, S. et al. (2013). Estimated dopamine D(2) receptor occupancy and remission in schizophrenia: analysis of the CATIE data."
  },
  {
    "citation": "Morimoto, K. et al. (2002). Delusional disorder: molecular genetic evidence for dopamine psychosis."
  },
  {
    "citation": "Morozova, M. et al. (2022). Treatment Response and GWAS Risk Allele rs2514218 (C) of the Dopamine D2 Receptor Gene in Inpatients with Schizophrenia."
  },
  {
    "citation": "Morrissette, D. et al. (2014). Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy."
  },
  {
    "citation": "Mosquera, M. et al. (2022). Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors."
  },
  {
    "citation": "Mouly, S. et al. (2015). Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity."
  },
  {
    "citation": "Muhetaer, H. et al. (2025). Exploring the Effects and Mechanisms of Valerian Volatile Oil in Treating Insomnia Using Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation-Based Approaches."
  },
  {
    "citation": "Mukda, S. et al. (2009). Amphetamine-induced changes in dopamine receptors in early postnatal rat brain."
  },
  {
    "citation": "Mukoyama, N. et al. (2016). An Analysis of Behavioral and Genetic Risk Factors for Chemotherapy-Induced Nausea and Vomiting in Japanese Subjects."
  },
  {
    "citation": "Mullally, J. et al. (2021). Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study."
  },
  {
    "citation": "Muller, D. et al. (2012). Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain."
  },
  {
    "citation": "Muro, G. et al. (2024). The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells."
  },
  {
    "citation": "Nagai, G. et al. (2012). Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia."
  },
  {
    "citation": "Nair, A. et al. (2020). An update on the efficacy and safety of iloperidone as a schizophrenia therapy."
  },
  {
    "citation": "Naito, T. et al. (2019). Optimization of Individual Pharmacotherapy Based on Multiple Evaluations of Patient Data."
  },
  {
    "citation": "Nakata, Y. et al. (2017). Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice."
  },
  {
    "citation": "Nakazono, Y. et al. (2005). Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients."
  },
  {
    "citation": "Nasyrova, R. et al. (2023). Single-Nucleotide Polymorphisms as Biomarkers of Antipsychotic-Induced Akathisia: Systematic Review."
  },
  {
    "citation": "Naumovska, Z. et al. (2015). Pharmacogenetics and antipsychotic treatment response."
  },
  {
    "citation": "Neto, L. et al. (2015). Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy."
  },
  {
    "citation": "Nguyen, H. et al. (2023). Neurotherapeutic Effects of Quercetin and Its Metabolite Compounds on Cognitive Impairment and Parkinson's Disease: An In Silico Study."
  },
  {
    "citation": "Nguyen, H. et al. (2023). Risperidone ameliorated 1,2-Diacetylbenzene-induced cognitive impairments in mice via activating prolactin signaling pathways."
  },
  {
    "citation": "Nielson, J. et al. (2017). Uncovering precision phenotype-biomarker associations in traumatic brain injury using topological data analysis."
  },
  {
    "citation": "Nishibe, H. et al. (2021). Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia."
  },
  {
    "citation": "Nohesara, S. et al. (2016). Methamphetamine-induced psychosis is associated with DNA hypomethylation and increased expression of AKT1 and key dopaminergic genes."
  },
  {
    "citation": "Nuntamool, N. et al. (2017). Pharmacogenomics and Efficacy of Risperidone Long-Term Treatment in Thai Autistic Children and Adolescents."
  },
  {
    "citation": "Odia, Y. et al. (2024). Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort."
  },
  {
    "citation": "Oh, H. et al. (2021). Role of rs6265 BDNF polymorphisms and post-stroke dysphagia recovery-A prospective cohort study."
  },
  {
    "citation": "Oishi, K. et al. (2018). Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia."
  },
  {
    "citation": "Oki, M. et al. (2017). Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats."
  },
  {
    "citation": "Okita, K. et al. (2016). Relationship of Alexithymia Ratings to Dopamine D2-type Receptors in Anterior Cingulate and Insula of Healthy Control Subjects but Not Methamphetamine-Dependent Individuals."
  },
  {
    "citation": "Olasore, H. et al. (2025). Dopamine receptor D2 (DRD2) TaqIA gene polymorphism and acute risperidone-induced changes in body weight, plasma glucose and lipid profile."
  },
  {
    "citation": "Olsen, D. et al. (2021). Altered dopaminergic firing pattern and novelty response underlie ADHD-like behavior of SorCS2-deficient mice."
  },
  {
    "citation": "Ooteman, W. et al. (2009). Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators."
  },
  {
    "citation": "Ortez, C. et al. (2015). Cerebrospinal fluid synaptic proteins as useful biomarkers in tyrosine hydroxylase deficiency."
  },
  {
    "citation": "Ortiz, D. et al. (2021). The dopaminergic alterations induced by 4-F-PCP and 4-Keto-PCP may enhance their drug-induced rewarding and reinforcing effects: Implications for abuse."
  },
  {
    "citation": "Osmanova, D. et al. (2019). A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia."
  },
  {
    "citation": "Ozzoude, M. et al. (2019). The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data."
  },
  {
    "citation": "Paderina, D. et al. (2022). The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia."
  },
  {
    "citation": "Pagerols, M. et al. (2017). Pharmacogenetics of methylphenidate response and tolerability in attention-deficit/hyperactivity disorder."
  },
  {
    "citation": "Palma, G. et al. (2010). A case-control study of Parkinson's disease and tobacco use: gene-tobacco interactions."
  },
  {
    "citation": "Pan, B. et al. (2023). Integrative multilevel exploration of the mechanism by which Er-Zhi-Wan alleviates the Parkinson's disease (PD)-like phenotype in the MPTP-induced PD mouse model."
  },
  {
    "citation": "Papenberg, G. et al. (2017). Dopamine Receptor Genes Modulate Associative Memory in Old Age."
  },
  {
    "citation": "Parande, F. et al. (2022). Effect of Dietary Grapes on Female C57BL6/J Mice Consuming a High-Fat Diet: Behavioral and Genetic Changes."
  },
  {
    "citation": "Parkman, H. et al. (2012). Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters."
  },
  {
    "citation": "Parkman, H. et al. (2011). Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects."
  },
  {
    "citation": "Passos, V. et al. (2009). Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists."
  },
  {
    "citation": "Patriquin, M. et al. (2015). Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system."
  },
  {
    "citation": "Paus, S. et al. (2008). The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease."
  },
  {
    "citation": "Pearson, A. et al. (2025). Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration."
  },
  {
    "citation": "Pecina, M. et al. (2017). Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response."
  },
  {
    "citation": "Peculis, R. et al. (2016). Polymorphisms in MEN1 and DRD2 genes are associated with the occurrence and characteristics of pituitary adenomas."
  },
  {
    "citation": "Pelzer, E. et al. (2022). Clustering of Parkinson subtypes reveals strong influence of DRD2 polymorphism and gender."
  },
  {
    "citation": "Peng, H. et al. (2022). Intestinal Dopamine Receptor D2 is Required for Neuroprotection Against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Dopaminergic Neurodegeneration."
  },
  {
    "citation": "Pergola, G. et al. (2017). DRD2 co-expression network and a related polygenic index predict imaging, behavioral and clinical phenotypes linked to schizophrenia."
  },
  {
    "citation": "Peroutka, S. et al. (1997). Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles."
  },
  {
    "citation": "Perrone, M. et al. (2021). Diffuse Intrinsic Pontine Glioma (DIPG): Breakthrough and Clinical Perspective."
  },
  {
    "citation": "Petersson, K. et al. (2013). Predictions of in vivo prolactin levels from in vitro K(i) values of D(2) receptor antagonists using an agonist-antagonist interaction model."
  },
  {
    "citation": "Philpott, A. et al. (2016). A GABBR2 gene variant modifies pathophysiology in Huntington's disease."
  },
  {
    "citation": "Pierce, S. et al. (2021). Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer."
  },
  {
    "citation": "Pieri, M. et al. (2023). Functional single nucleotide polymorphisms in dopaminergic receptors D2 predict clinical response to Cariprazine."
  },
  {
    "citation": "Piovesan, E. et al. (2000). [Change in the biological pattern of migraine with aura after the use of tetrabenazine: case report]."
  },
  {
    "citation": "Pivonello, C. et al. (2017). Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study."
  },
  {
    "citation": "Politi, C. et al. (2018). Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies."
  },
  {
    "citation": "Politis, M. et al. (2017). Chronic exposure to dopamine agonists affects the integrity of striatal D(2) receptors in Parkinson's patients."
  },
  {
    "citation": "Prabhu, V. et al. (2020). ONC201 and imipridones: Anti-cancer compounds with clinical efficacy."
  },
  {
    "citation": "Prabhu, V. et al. (2019). Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism."
  },
  {
    "citation": "Puangpetch, A. et al. (2019). Association between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia."
  },
  {
    "citation": "Punchaichira, T. et al. (2020). The effect of rs1076560 (DRD2) and rs4680 (COMT) on tardive dyskinesia and cognition in schizophrenia subjects."
  },
  {
    "citation": "Putnam, D. et al. (2011). Exploring schizophrenia drug-gene interactions through molecular network and pathway modeling."
  },
  {
    "citation": "Qi, J. et al. (2002). [Study on the association between smoking behavior and dopamine receptor D2 gene polymorphisms among lung cancer cases]."
  },
  {
    "citation": "Qin, Y. et al. (2024). DRD2 TaqIA polymorphism-related functional connectivity between anterior insula and dorsolateral prefrontal cortex predicts the retention time in heroin-dependent individuals under methadone maintenance treatment."
  },
  {
    "citation": "Qing, J. et al. (2022). Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis."
  },
  {
    "citation": "Qiu, J. et al. (2016). Sinomenine activates astrocytic dopamine D2 receptors and alleviates neuroinflammatory injury via the CRYAB/STAT3 pathway after ischemic stroke in mice."
  },
  {
    "citation": "Qu, K. et al. (2024). Association Study Between DRD2, DRD3 Genetic Polymorphisms and Adverse Reactions in Chinese Patients on Amisulpride Treatment."
  },
  {
    "citation": "Radojevic, B. et al. (2022). The correlation between genetic factors and freezing of gait in patients with Parkinson's disease."
  },
  {
    "citation": "Radojevic, B. et al. (2021). Clinical and Genetic Analysis of Psychosis in Parkinson's Disease."
  },
  {
    "citation": "Ramoz, N. et al. (2015). [A genetic view of addiction]."
  },
  {
    "citation": "Rebelo, D. et al. (2021). A link between synaptic plasticity and reorganization of brain activity in Parkinson's disease."
  },
  {
    "citation": "Recouvreux, M. et al. (2011). Active and total transforming growth factor-beta1 are differentially regulated by dopamine and estradiol in the pituitary."
  },
  {
    "citation": "Redensek, S. et al. (2020). Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease."
  },
  {
    "citation": "Richter, F. et al. (2014). Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons."
  },
  {
    "citation": "Rieck, M. et al. (2018). Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease."
  },
  {
    "citation": "Rieck, M. et al. (2012). DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients."
  },
  {
    "citation": "Robinson, J. et al. (2007). The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms."
  },
  {
    "citation": "Rochowiak, E. et al. (2022). Studies on candidate genes for lithium prophylaxis performed at the Poznan University of Medical Sciences."
  },
  {
    "citation": "Rodrigues, A. et al. (2012). Mechanisms of initiation and reversal of drug-seeking behavior induced by prenatal exposure to glucocorticoids."
  },
  {
    "citation": "Rodriguez, R. et al. (2013). Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers."
  },
  {
    "citation": "Roke, Y. et al. (2013). The effect of the Taq1A variant in the dopamine D(2) receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys."
  },
  {
    "citation": "Romany, I. et al. (2020). Biological activity of weekly ONC201 in adult recurrent glioblastoma patients."
  },
  {
    "citation": "Rominger, A. et al. (2013). Effects of acute detoxification of the herbal blend 'Spice Gold' on dopamine D2/3 receptor availability: a [18F]fallypride PET study."
  },
  {
    "citation": "Rossetti, M. et al. (2020). Epigenetic Dysregulation of Dopaminergic System by Maternal Cafeteria Diet During Early Postnatal Development."
  },
  {
    "citation": "Rossow, K. et al. (2021). Evidence for Pharmacogenomic Effects on Risperidone Outcomes in Pediatrics."
  },
  {
    "citation": "Russo, E. et al. (2022). Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation."
  },
  {
    "citation": "Ruyck, K. et al. (2010). Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients."
  },
  {
    "citation": "Rybakowski, J. et al. (2012). Clinical and pathogenic aspects of candidate genes for lithium prophylactic efficacy."
  },
  {
    "citation": "Saghazadeh, A. et al. (2016). Genetic polymorphisms and the adequacy of brain stimulation: state of the art."
  },
  {
    "citation": "Sakumoto, N. et al. (2007). Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia."
  },
  {
    "citation": "Sakurai, H. et al. (2013). Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data."
  },
  {
    "citation": "Salloum, N. et al. (2018). From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation."
  },
  {
    "citation": "Sanchez, C. et al. (2017). Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects."
  },
  {
    "citation": "Sangrajrang, S. et al. (2010). Genetic polymorphisms in folate and alcohol metabolism and breast cancer risk: a case-control study in Thai women."
  },
  {
    "citation": "Sanguesa, E. et al. (2024). Impact of Pharmacogenetic Testing on Clozapine Treatment Efficacy in Patients with Treatment-Resistant Schizophrenia."
  },
  {
    "citation": "Santos, L. et al. (2021). Perinatal exposure to a high-fat diet alters proopiomelanocortin, neuropeptide Y and dopaminergic receptors gene expression and the food preference in offspring adult rats."
  },
  {
    "citation": "Santos, E. et al. (2020). Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study."
  },
  {
    "citation": "Santos, E. et al. (2019). Pharmacogenetic Profile and the Occurrence of Visual Hallucinations in Patients With Sporadic Parkinson's Disease."
  },
  {
    "citation": "Santos, E. et al. (2019). The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's disease."
  },
  {
    "citation": "Saung, W. et al. (2014). Lack of influence of DAT1 and DRD2 gene variants on antidepressant response in generalized anxiety disorder."
  },
  {
    "citation": "Saveanu, A. et al. (2009). Somatostatin-dopamine ligands in the treatment of pituitary adenomas."
  },
  {
    "citation": "Schacht, J. et al. (2018). Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial."
  },
  {
    "citation": "Schacht, J. et al. (2016). COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review."
  },
  {
    "citation": "Schafer, M. et al. (2001). Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene."
  },
  {
    "citation": "Scharfetter, J. et al. (2004). Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update."
  },
  {
    "citation": "Schrantee, A. et al. (2017). Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate."
  },
  {
    "citation": "Schuh, A. et al. (2014). Parkinson's disease pharmacogenomics: new findings and perspectives."
  },
  {
    "citation": "Schuster, J. et al. (2024). In-depth analysis of data from the RAS-ALS study reveals new insights in rasagiline treatment for amyotrophic lateral sclerosis."
  },
  {
    "citation": "Seeman, P. et al. (2016). Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose."
  },
  {
    "citation": "Segman, R. et al. (2003). Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia."
  },
  {
    "citation": "Serretti, A. et al. (2004). Genetic features of antidepressant induced mania and hypo-mania in bipolar disorder."
  },
  {
    "citation": "Serretti, A. et al. (2001). No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors."
  },
  {
    "citation": "Serretti, A. et al. (1999). Dopamine receptor D2 and D4 genes, GABA(A) alpha-1 subunit genes and response to lithium prophylaxis in mood disorders."
  },
  {
    "citation": "Severino, G. et al. (2003). Pharmacogenomics: state of the research and perspectives in clinical application."
  },
  {
    "citation": "Sharo, C. et al. (2024). Repurposing FDA-Approved Drugs Against Potential Drug Targets Involved in Brain Inflammation Contributing to Alzheimer's Disease."
  },
  {
    "citation": "She, X. et al. (2021). A high-throughput screen identifies inhibitors of lung cancer stem cells."
  },
  {
    "citation": "Shen, Y. et al. (2009). Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients."
  },
  {
    "citation": "Shi, L. et al. (2023). The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma."
  },
  {
    "citation": "Shi, Y. et al. (2017). Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients."
  },
  {
    "citation": "Shi, S. et al. (2014). MicroRNA-9 and microRNA-326 regulate human dopamine D2 receptor expression, and the microRNA-mediated expression regulation is altered by a genetic variant."
  },
  {
    "citation": "Shilbayeh, S. et al. (2024). The polymorphisms of candidate pharmacokinetic and pharmacodynamic genes and their pharmacogenetic impacts on the effectiveness of risperidone maintenance therapy among Saudi children with autism."
  },
  {
    "citation": "Shimazu, S. et al. (2012). Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels."
  },
  {
    "citation": "Shiroma, P. et al. (2010). Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry."
  },
  {
    "citation": "Singleton, A. et al. (1998). Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population."
  },
  {
    "citation": "Smiarowska, M. et al. (2022). Influence of COMT (rs4680) and DRD2 (rs1076560, rs1800497) Gene Polymorphisms on Safety and Efficacy of Methylphenidate Treatment in Children with Fetal Alcohol Spectrum Disorders."
  },
  {
    "citation": "Smith, H. et al. (2010). The role of genomic oxidative-reductive balance as predictor of complex regional pain syndrome development: a novel theory."
  },
  {
    "citation": "Somogyi, A. et al. (2014). Pharmacogenomics of methadone maintenance treatment."
  },
  {
    "citation": "Song, Y. et al. (2020). Thioridazine hydrochloride: an antipsychotic agent that inhibits tumor growth and lung metastasis in triple-negative breast cancer via inducing G0/G1 arrest and apoptosis."
  },
  {
    "citation": "Soraya, G. et al. (2022). Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis."
  },
  {
    "citation": "Spellicy, C. et al. (2013). ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse."
  },
  {
    "citation": "Spiros, A. et al. (2017). Semi-mechanistic computer simulation of psychotic symptoms in schizophrenia with a model of a humanized cortico-striatal-thalamocortical loop."
  },
  {
    "citation": "Spitta, G. et al. (2022). Association between DRD2/ANKK1 TaqIA Allele Status and Striatal Dopamine D2/3 Receptor Availability in Alcohol Use Disorder."
  },
  {
    "citation": "Sriram, K. et al. (2014). Neurotoxicity following acute inhalation of aerosols generated during resistance spot weld-bonding of carbon steel."
  },
  {
    "citation": "Staley, A. et al. (2021). Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer."
  },
  {
    "citation": "Starkiewicz, A. et al. (2024). Identification of genes regulated by trait sensitivity to negative feedback and prolonged alcohol consumption in rats."
  },
  {
    "citation": "Stefan, P. et al. (2009). Development of a high-throughput method for screening the dopamine D2 (DRD2) receptor gene polymorphisms based on the LightCycler system."
  },
  {
    "citation": "Stein, M. et al. (2019). Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration."
  },
  {
    "citation": "Stein, M. et al. (2017). First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors."
  },
  {
    "citation": "Stelmach, A. et al. (2023). Antipsychotic drug-aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms."
  },
  {
    "citation": "Strecker, K. et al. (2012). The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice."
  },
  {
    "citation": "Su, T. et al. (2025). The dopamine receptor agonist rotigotine attenuated indomethacin-induced enteropathy in the small intestinal mucosa of mice."
  },
  {
    "citation": "Suchanecka, A. et al. (2011). [ANKK1 gene in psychiatry]."
  },
  {
    "citation": "Sukasem, C. et al. (2018). Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder."
  },
  {
    "citation": "Sukasem, C. et al. (2016). Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders."
  },
  {
    "citation": "Suzuki, A. et al. (2001). Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome."
  },
  {
    "citation": "Suzuki, A. et al. (2001). The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients."
  },
  {
    "citation": "Suzuki, A. et al. (2001). Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report."
  },
  {
    "citation": "Suzuki, A. et al. (2000). The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients."
  },
  {
    "citation": "Swan, G. et al. (2007). Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR."
  },
  {
    "citation": "Swan, G. et al. (2005). Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR."
  },
  {
    "citation": "Sykes, D. et al. (2017). Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D(2) receptors."
  },
  {
    "citation": "Taheri, N. et al. (2023). Association of DRD2, DRD4 and COMT genes variants and their gene-gene interactions with antipsychotic treatment response in patients with schizophrenia."
  },
  {
    "citation": "Takahashi, Y. et al. (2021). Aberrant neurogenesis and late onset suppression of synaptic plasticity as well as sustained neuroinflammation in the hippocampal dentate gyrus after developmental exposure to ethanol in rats."
  },
  {
    "citation": "Tan, H. et al. (2012). Effective connectivity of AKT1-mediated dopaminergic working memory networks and pharmacogenetics of anti-dopaminergic treatment."
  },
  {
    "citation": "Tang, H. et al. (2023). DRD2 expression based on (18)F-fallypride PET/MR predicts the dopamine agonist resistance of prolactinomas: a pilot study."
  },
  {
    "citation": "Tang, H. et al. (2021). Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists."
  },
  {
    "citation": "Tanrikulu, B. et al. (2023). Preliminary findings of German-sourced ONC201 treatment in H3K27 altered pediatric pontine diffuse midline gliomas."
  },
  {
    "citation": "Tarland, E. et al. (2018). Effects of 2-bromoterguride, a dopamine D(2) receptor partial agonist, on cognitive dysfunction and social aversion in rats."
  },
  {
    "citation": "Tashiro, M. et al. (2014). Impact of genetic and non-genetic factors on clinical responses to prochlorperazine in oxycodone-treated cancer patients."
  },
  {
    "citation": "Tashkin, D. et al. (2012). Association of dopamine-related gene alleles, smoking behavior and decline in FEV1 in subjects with COPD: findings from the lung health study."
  },
  {
    "citation": "Tavares, G. et al. (2021). Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes."
  },
  {
    "citation": "Teh, L. et al. (2012). Tridimensional personalities and polymorphism of dopamine D2 receptor among heroin addicts."
  },
  {
    "citation": "Teng, Y. et al. (2023). The Progress and Pitfalls of Pharmacogenetics-Based Precision Medicine in Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis."
  },
  {
    "citation": "Terrazzino, S. et al. (2010). The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients."
  },
  {
    "citation": "Terzic, T. et al. (2016). Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia."
  },
  {
    "citation": "Thangaraj, A. et al. (2020). Mitigation of cocaine-mediated mitochondrial damage, defective mitophagy and microglial activation by superoxide dismutase mimetics."
  },
  {
    "citation": "Thelma, B. et al. (2008). Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics."
  },
  {
    "citation": "Thompson, J. et al. (1997). D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele."
  },
  {
    "citation": "Tomaz, P. et al. (2015). CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy."
  },
  {
    "citation": "Tozzi, A. et al. (2018). Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease."
  },
  {
    "citation": "Tsai, S. et al. (2004). Dopamine receptor downregulation: an alternative strategy for schizophrenia treatment."
  },
  {
    "citation": "Tsuneki, H. et al. (2016). Nighttime Administration of Nicotine Improves Hepatic Glucose Metabolism via the Hypothalamic Orexin System in Mice."
  },
  {
    "citation": "Tucker, K. et al. (2022). ONC206 has anti-tumorigenic effects in human ovarian cancer cells and in a transgenic mouse model of high-grade serous ovarian cancer."
  },
  {
    "citation": "Tung, M. et al. (2022). Targeting DRD2 by the antipsychotic drug, penfluridol, retards growth of renal cell carcinoma via inducing stemness inhibition and autophagy-mediated apoptosis."
  },
  {
    "citation": "Tybura, P. et al. (2014). Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine."
  },
  {
    "citation": "Tybura, P. et al. (2012). Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients."
  },
  {
    "citation": "Tybura, P. et al. (2011). [Associations between candidate genes with schizophrenia susceptibility and the treatment efficiency]."
  },
  {
    "citation": "Ujike, H. et al. (2009). Genetic variants of D2 but not D3 or D4 dopamine receptor gene are associated with rapid onset and poor prognosis of methamphetamine psychosis."
  },
  {
    "citation": "Utsumi, H. et al. (2013). Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease."
  },
  {
    "citation": "Vandenbergh, D. et al. (2007). Dopamine receptor genes (DRD2, DRD3 and DRD4) and gene-gene interactions associated with smoking-related behaviors."
  },
  {
    "citation": "Vehof, J. et al. (2012). Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes."
  },
  {
    "citation": "Veselinovic, T. et al. (2019). Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial."
  },
  {
    "citation": "Vicchi, F. et al. (2022). Severe Hyperprolactinemia Promotes Brown Adipose Tissue Whitening and Aggravates High Fat Diet Induced Metabolic Imbalance."
  },
  {
    "citation": "Viviani, R. et al. (2014). Use of magnetic resonance imaging in pharmacogenomics."
  },
  {
    "citation": "Volkow, N. et al. (2015). Recovery of dopamine transporters with methamphetamine detoxification is not linked to changes in dopamine release."
  },
  {
    "citation": "Vulink, N. et al. (2012). Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder."
  },
  {
    "citation": "Wang, Y. et al. (2023). Chronic stress accelerates glioblastoma progression via DRD2/ERK/beta-catenin axis and Dopamine/ERK/TH positive feedback loop."
  },
  {
    "citation": "Wang, Z. et al. (2023). Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Patients with Schizophrenia: A Randomized Controlled Trial."
  },
  {
    "citation": "Wang, X. et al. (2023). Network pharmacology and LC-MS approachs to explore the active compounds and mechanisms of Yuanjiang decoction for treating bradyarrhythmia."
  },
  {
    "citation": "Wang, J. et al. (2022). The D2R-DISC1 protein complex and associated proteins are altered in schizophrenia and normalized with antipsychotic treatment."
  },
  {
    "citation": "Wang, S. et al. (2021). The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas."
  },
  {
    "citation": "Wang, D. et al. (2020). Pharmacogenomics analysis in Chinese pediatric liver transplantation patients with renal toxicity induced by tacrolimus."
  },
  {
    "citation": "Wang, X. et al. (2019). The Prospective Value of Dopamine Receptors on Bio-Behavior of Tumor."
  },
  {
    "citation": "Wang, Y. et al. (2019). Prenatal Tobacco Exposure Modulated the Association of Genetic variants with Diagnosed ADHD and its symptom domain in children: A Community Based Case-Control Study."
  },
  {
    "citation": "Wang, D. et al. (2015). Studies on the regulatory effect of Peony-Glycyrrhiza Decoction on prolactin hyperactivity and underlying mechanism in hyperprolactinemia rat model."
  },
  {
    "citation": "Wang, Y. et al. (2012). The role of single nucleotide polymorphism of D2 dopamine receptor gene on major depressive disorder and response to antidepressant treatment."
  },
  {
    "citation": "Wang, H. et al. (2011). [Effect of Bushen Huoxue Decoction on dopamine D2 receptor in the brain of rats with Parkinson's disease]."
  },
  {
    "citation": "Weenen, J. et al. (2011). Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice."
  },
  {
    "citation": "Weenen, J. et al. (2011). Blocking dopamine D2 receptors by haloperidol curtails the beneficial impact of calorie restriction on the metabolic phenotype of high-fat diet induced obese mice."
  },
  {
    "citation": "Wei, S. et al. (2021). Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson's disease."
  },
  {
    "citation": "Wei, L. et al. (2015). Dopamine receptor DR2 expression in B cells is negatively correlated with disease activity in rheumatoid arthritis patients."
  },
  {
    "citation": "White, O. et al. (2022). Prenatal Effects of Nicotine on Obesity Risks: A Narrative Review."
  },
  {
    "citation": "Whiting, R. et al. (2021). Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D(2)/D(3) Receptor Antagonist for the Management of Gastroparesis."
  },
  {
    "citation": "Wieting, J. et al. (2023). Hypomethylation of the dopamine transporter (DAT) gene promoter is associated with hyperphagia-related behavior in Prader-Willi syndrome: A case-control study."
  },
  {
    "citation": "Wilcox, C. et al. (2011). ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data."
  },
  {
    "citation": "Winsberg, B. et al. (1999). Association of the dopamine transporter gene (DAT1) with poor methylphenidate response."
  },
  {
    "citation": "Wit, I. et al. (2017). Dopamine D2-receptor affinity of antipsychotics in relation to subjective well-being in patients with a psychotic disorder."
  },
  {
    "citation": "Wojcieszak, J. et al. (2025). Access to high-fat diet results in increased sensitivity to the psychostimulant effects of MDPV in mice."
  },
  {
    "citation": "Wolfe, D. et al. (2018). Drug Refraining and Seeking Potentiate Synapses on Distinct Populations of Accumbens Medium Spiny Neurons."
  },
  {
    "citation": "Wong, A. et al. (2023). Effect of gene variants on opioid dose, pain and adverse effect outcomes in advanced cancer: an explorative study."
  },
  {
    "citation": "Wu, D. et al. (2018). Inhibition of microRNA-200a Upregulates the Expression of Striatal Dopamine Receptor D2 to Repress Apoptosis of Striatum via the cAMP/PKA Signaling Pathway in Rats with Parkinson's Disease."
  },
  {
    "citation": "Wu, S. et al. (2006). Association of DRD2 polymorphisms and chlorpromazine-induced extrapyramidal syndrome in Chinese schizophrenic patients."
  },
  {
    "citation": "Wu, S. et al. (2005). Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients."
  },
  {
    "citation": "Xin, J. et al. (2022). To explore the potential molecular mechanism of complex rose-bergamot essential oil on anti-anxiety with facial spots based on network pharmacology."
  },
  {
    "citation": "Xing, Q. et al. (2007). The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients."
  },
  {
    "citation": "Xu, C. et al. (2021). Effects of Yuanhu- Zhitong tablets on alcohol-induced conditioned place preference in mice."
  },
  {
    "citation": "Xu, Z. et al. (2018). SP8 and SP9 coordinately promote D2-type medium spiny neuron production by activating Six3 expression."
  },
  {
    "citation": "Xu, S. et al. (2017). Association of the DRD2 CA(n)-STR and DRD3 Ser9Gly polymorphisms with Parkinson's disease and response to dopamine agonists."
  },
  {
    "citation": "Xu, Z. et al. (2011). Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response."
  },
  {
    "citation": "Yamanouchi, Y. et al. (2003). Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone."
  },
  {
    "citation": "Yan, J. et al. (2023). Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease."
  },
  {
    "citation": "Yan, Q. et al. (2022). HERV-W Envelope Triggers Abnormal Dopaminergic Neuron Process through DRD2/PP2A/AKT1/GSK3 for Schizophrenia Risk."
  },
  {
    "citation": "Yan, P. et al. (2020). Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients."
  },
  {
    "citation": "Yang, Y. et al. (2022). Xiaoyao San ameliorates high-fat diet-induced anxiety and depression via regulating gut microbiota in mice."
  },
  {
    "citation": "Yang, Y. et al. (2022). Salvianolic acid A relieves cognitive disorder after chronic cerebral ischemia: Involvement of Drd2/Cryab/NF-kappaB pathway."
  },
  {
    "citation": "Yang, Y. et al. (2018). Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer."
  },
  {
    "citation": "Yanovich, C. et al. (2018). Social rank-associated stress vulnerability predisposes individuals to cocaine attraction."
  },
  {
    "citation": "Yao, K. et al. (2025). Aripiprazole alleviates the high prolactin levels induced by amisulpride via distinct molecular mechanisms: a network pharmacology and molecular docking study."
  },
  {
    "citation": "Yao, Y. et al. (2008). Verification of proposed peripheral biomarkers in mononuclear cells of individuals with schizophrenia."
  },
  {
    "citation": "Yen, E. et al. (2023). Sex-specific inflammatory and white matter effects of prenatal opioid exposure: a pilot study."
  },
  {
    "citation": "Yen, E. et al. (2019). Sex-Dependent Gene Expression in Infants with Neonatal Opioid Withdrawal Syndrome."
  },
  {
    "citation": "Yin, L. et al. (2015). TPH, SLC6A2, SLC6A3, DRD2 and DRD4 Polymorphisms and Neuroendocrine Factors Predict SSRIs Treatment Outcome in the Chinese Population with Major Depression."
  },
  {
    "citation": "Ying, J. et al. (2023). Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review."
  },
  {
    "citation": "Yoshida, K. et al. (2021). Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review."
  },
  {
    "citation": "Young, R. et al. (2004). Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele."
  },
  {
    "citation": "Yu, J. et al. (2025). Transcriptomic analysis and experiment to verify the mechanism of Xiaoyao san in the treatment of irritable bowel syndrome with depression."
  },
  {
    "citation": "Zahari, Z. et al. (2020). Influence of DRD2 Polymorphisms on the Clinical Outcomes of Opioiddependent Patients on Methadone Maintenance Therapy."
  },
  {
    "citation": "Zahari, Z. et al. (2011). A Nested Allele-Specific Multiplex Polymerase Chain Reaction Method for the Detection of DRD2 Polymorphisms."
  },
  {
    "citation": "Zahari, Z. et al. (2011). Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia."
  },
  {
    "citation": "Zai, C. et al. (2018). Genetics of tardive dyskinesia: Promising leads and ways forward."
  },
  {
    "citation": "Zai, C. et al. (2009). Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients."
  },
  {
    "citation": "Zai, C. et al. (2008). Genetic study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms in tardive dyskinesia."
  },
  {
    "citation": "Zai, C. et al. (2007). Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients."
  },
  {
    "citation": "Zakharyan, R. et al. (2020). Association of Genetic Variants of Dopamine and Serotonin In Schizophrenia."
  },
  {
    "citation": "Zappia, M. et al. (2005). Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study."
  },
  {
    "citation": "Zarrin, P. et al. (2021). Liposomal Form of L-Dopa and SH-Sy5y Cell-Derived Exosomes Modulate the Tyrosine Hydroxylase/Dopamine Receptor D2 Signaling Pathway in Parkinson's Rat Models."
  },
  {
    "citation": "Zastrozhin, M. et al. (2017). Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder."
  },
  {
    "citation": "Zazueta, A. et al. (2022). Polymorphisms in Schizophrenia-Related Genes Are Potential Predictors of Antipsychotic Treatment Resistance and Refractoriness."
  },
  {
    "citation": "Zhang, Y. et al. (2024). Recent Advances in representative small-molecule DRD2 inhibitors: Synthetic Routes and clinical applications."
  },
  {
    "citation": "Zhang, J. et al. (2021). Methylation quantitative trait locus rs5326 is associated with susceptibility and effective dosage of methadone maintenance treatment for heroin use disorder."
  },
  {
    "citation": "Zhang, Y. et al. (2020). ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro."
  },
  {
    "citation": "Zhang, J. et al. (2018). Recent Progress in Pharmacogenomics of Antipsychotic Drug Response."
  },
  {
    "citation": "Zhang, J. et al. (2016). Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis."
  },
  {
    "citation": "Zhang, J. et al. (2015). Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis."
  },
  {
    "citation": "Zhang, X. et al. (2011). Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes."
  },
  {
    "citation": "Zhang, J. et al. (2010). D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis."
  },
  {
    "citation": "Zhang, L. et al. (2004). [Molecular pharmacogenetic studies of drug responses to obsessive-compulsive disorder and six functional genes]."
  },
  {
    "citation": "Zhang, Z. et al. (2003). [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)]."
  },
  {
    "citation": "Zhang, Z. et al. (2003). No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response."
  },
  {
    "citation": "Zhao, J. et al. (2019). Different roles of Rac1 in the acquisition and extinction of methamphetamine-associated contextual memory in the nucleus accumbens."
  },
  {
    "citation": "Zhu, X. et al. (2011). Stress-induced depressive behaviors are correlated with Par-4 and DRD2 expression in rat striatum."
  },
  {
    "citation": "Zivkovic, M. et al. (2020). Remission Is not Associated with DRD2 rs1800497 and DAT1 rs28363170 Genetic Variants in Male Schizophrenic Patients after 6-months Monotherapy with Olanzapine."
  },
  {
    "citation": "Zivkovic, M. et al. (2013). The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol."
  },
  {
    "citation": "Zivkovic, M. et al. (2010). The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes."
  },
  {
    "citation": "Zorick, T. et al. (2019). Effects of Citalopram on Cue-Induced Alcohol Craving and Thalamic D2/3 Dopamine Receptor Availability."
  },
  {
    "citation": "Zubiaur, P. et al. (2021). The pharmacogenetics of treatment with olanzapine."
  },
  {
    "citation": "Zubiaur, P. et al. (2021). Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers."
  }
]